Connect with us

Life Sciences

Tom McDonald, CEO of Clerkenwell Health, Sits in the Investor Hotseat on January 9th

During this edition of the Investor Hotseat, host Dustin Robinson of Iter Investments is joined by Tom McDonald of Clerkenwell Health. Clerkenwell Health…

Published

on

This article was originally published by Psychedelic Invest

During this edition of the Investor Hotseat, host Dustin Robinson of Iter Investments is joined by Tom McDonald of Clerkenwell Health.

Clerkenwell Health is a leading psychedelic specialty CRO offering specialist trial design, regulatory submission, and trial delivery services.

Tom’s background is in the biopharmaceutical sector including 18 months at IQVIA (formerly Quintilles-IMS, the world’s largest CRO) alongside experience across 5 of the global top 10 pharma companies.

How will Tom handle the hot seat? Tune in to find out.

As always, this will be a live event. You’ll be able to stream it from the Psychedelic Invest website, YouTube, LinkedIn, Facebook, Twitch, and Twitter. If you miss it, though, don’t worry. It will be recorded and available across those channels after the event.

If you’d like to attend the live event, you can set a reminder on Youtube or LinkedIn. Or, you can return to the Hotseat livestream page at the time of the event.

To RSVP to ensure your spot, please fill out the form below.

A Transcription Will Be Available Following the Event

cro
biopharmaceutical

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending